 "Zydus Cadila receives US FDA nod for anti-fungal drug fluconazole tablet")
Zydus Cadila has received the final approval from the US Food and Drug Administration (FDA) to market fluconazole tablet in strengthens of 50 mg, 100 mg, 150 mg & 200 mg, and clobetasol propionate spray (0.05%).
Fluconazole tablet, which is used to treat fungal infections, will be produced at the group's formulation manufacturing facility at Baddi.
Clobetasol propionate spray, used in the treatment of various skin disorders, will be manufactured at the group's dedicated topical plant located at Changodar (Ahmedabad).
With this, the group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%